Analysts expect Heat Biologics Inc (NASDAQ:HTBX) to report ($0.15) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Heat Biologics’ earnings. Heat Biologics also posted earnings per share of ($0.15) in the same quarter last year. The business is scheduled to announce its next quarterly earnings report on Thursday, March 26th.
According to Zacks, analysts expect that Heat Biologics will report full-year earnings of ($0.61) per share for the current fiscal year. For the next financial year, analysts anticipate that the company will report earnings of ($0.61) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Heat Biologics.
A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. boosted its holdings in shares of Heat Biologics Inc (NASDAQ:HTBX) by 6.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,327,660 shares of the biopharmaceutical company’s stock after acquiring an additional 84,400 shares during the quarter. Vanguard Group Inc. owned 3.90% of Heat Biologics worth $909,000 at the end of the most recent quarter. 4.93% of the stock is owned by institutional investors.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Recommended Story: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.